Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data

Nyandele, JP; Kibondo, UA; Issa, F; Van Geertruyden, JP; Warimwe, G; Jongo, S; Abdulla, S; Olotu, A

Journal article

Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data

Abstract:: BackgroundPre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpoint, and efficacy was investigated by using surrogate endpoints of Plasmodium falciparum prepatent period, parasite density, and multiplication rates in a controlled human malaria infection trial (CHMI).MethodsWe evaluated the correlation between monocyte-to-lymphocyte ratio and RTS,S vaccine effectiveness using Cox regression modeling with clinical malaria as the primary endpoint. Of the 1704 participants in the RTS,S field trial, data on monocyte-to-lymphocyte ratio was available for 842 participants, of whom our analyses were restricted. We further used Spearman Correlations and Cox regression modeling to evaluate the correlation between monocyte-to-lymphocyte ratio and Whole Sporozoite malaria vaccine efficacy using the surrogate endpoints. Of the 97 participants in the controlled human malaria infection vaccine trials, hematology and parasitology information were available for 82 participants, of whom our analyses were restricted.ResultsThe unadjusted efficacy of RTS,S malaria vaccine was 54% (95% CI: 37%-66%, p ConclusionMonocyte-to-lymphocyte ratio alone may not be an adequate marker for malaria vaccine efficacy. Further investigations on immune correlates and underlying mechanisms of immune protection against malaria could provide a clearer explanation of the differences between those protected in comparison with those not protected against malaria by vaccination

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Nyandele, J. P., Kibondo, U. A., Issa, F., Van Geertruyden, J. P., Warimwe, G., Jongo, S., Abdulla, S., & Olotu, A. (2023). Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data. PLoS ONE, 18(9), e0291244–e0291244.

MLA Style

Nyandele, JP, et al. “Pre-Vaccination Monocyte-to-Lymphocyte Ratio as a Biomarker for the Efficacy of Malaria Candidate Vaccines: A Subgroup Analysis of Pooled Clinical Trial Data.” PLoS ONE, vol. 18, no. 9, 2023, pp. e0291244–e0291244.

Chicago Style

Nyandele, JP, UA Kibondo, F Issa, et al. 2023. “Pre-Vaccination Monocyte-to-Lymphocyte Ratio as a Biomarker for the Efficacy of Malaria Candidate Vaccines: A Subgroup Analysis of Pooled Clinical Trial Data.” PLoS ONE 18 (9): e0291244–e0291244.
Print